13F-HR filed by GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC. filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-08, with 6 holding rows worth $2,117,784,504.
- Accession
- 0001123292-26-000642
- Filer
- CIK 882095
- Filed
- 2026-05-08
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 6 entries on the cover page, a total value of $2,117,784,504 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,117,784,504 with VALUE read as dollars as filed, 13F file number 028-25078. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerGilead Therapeutics A1 Unlimited Co028-25083
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 6,720,803 | $771,682,600 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 31,424,760 | $678,774,816 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 16,707,477 | $501,224,310 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 4,505,391 | $125,024,600 | dollars as filed | |
| KYVERNA THERAPEUTICS INC | 501976104 | COMMON STOCK | 4,126,119 | $35,608,407 | dollars as filed | |
| Xilio Therapeutics Inc. | 98422T100 | COM | 650,389 | $5,469,771 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001123292-26-000642 | this filing | 2026-05-08 | acceptance time not in the bulk data set |